Amedeo Smart

Free Medical Literature Service

 

Amedeo

Diabetes
  Free Subscription

Articles published in
Kidney Int
    April 2025
  1. LI L, Liu Y
    Podocyte aging and diabetic kidney disease.
    Kidney Int. 2025;107:596-598.
    >> Share

    January 2025
  2. LI Y, Duan Y, Chu Q, Lv H, et al
    G-protein coupled receptor GPR124 protects against podocyte senescence and injury in diabetic kidney disease.
    Kidney Int. 2025 Jan 17:S0085-2538(25)00057-2. doi: 10.1016/j.kint.2024.
    >> Share

    December 2024
  3. MIMURA I, Chen Z, Natarajan R
    Epigenetic alterations and memory: key players in the development/progression of chronic kidney disease promoted by acute kidney injury and diabetes.
    Kidney Int. 2024 Dec 24:S0085-2538(24)00918-9. doi: 10.1016/j.kint.2024.
    >> Share

  4. FOLESTAD E, Mehlem A, Ning FC, Oosterveld T, et al
    Vascular endothelial growth factor B-mediated fatty acid flux in the adipose-kidney axis contributes to lipotoxicity in diabetic kidney disease.
    Kidney Int. 2024 Dec 15:S0085-2538(24)00872-X. doi: 10.1016/j.kint.2024.
    >> Share

  5. KRISHNAN S, Manoharan J, Wang H, Gupta D, et al
    Corrigendum to "CD248 induces a maladaptive unfolded protein response in diabetic kidney disease." Kidney International 2023;103:304-319.
    Kidney Int. 2024;106:1193-1196.
    >> Share

    November 2024
  6. LV Z, Hu J, Su H, Yu Q, et al
    TRAIL induces podocyte PANoptosis via death receptor 5 in diabetic kidney disease.
    Kidney Int. 2024 Nov 19:S0085-2538(24)00800-7. doi: 10.1016/j.kint.2024.
    >> Share

  7. MIYAMOTO S, Heerspink HJL, de Zeeuw D, Sakamoto K, et al
    A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope.
    Kidney Int. 2024;106:972-984.
    >> Share

    September 2024
  8. NARONGKIATIKHUN P, Bjornstad P
    Deciphering the kidney hemodynamic effects of SGLT2 inhibition: translating insights from rats to humans in type 2 diabetes.
    Kidney Int. 2024;106:354-356.
    >> Share

  9. VIVARELLI M, Barratt J, Beck LH Jr, Fakhouri F, et al
    The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
    Kidney Int. 2024;106:369-391.
    >> Share

    August 2024
  10. SELVARAJAH V, Robertson D, Hansen L, Jermutus L, et al
    A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.
    Kidney Int. 2024 Aug 30:S0085-2538(24)00629-X. doi: 10.1016/j.kint.2024.
    >> Share

    July 2024
  11. HEROLD JM, Wiegrebe S, Nano J, Jung B, et al
    Population-based reference values for kidney function and kidney function decline in 25- to 95-year-old Germans without and with diabetes.
    Kidney Int. 2024 Jul 29:S0085-2538(24)00528-3. doi: 10.1016/j.kint.2024.
    >> Share

  12. DRUEKE TB, Massy ZA
    Unexpected metabolic effects of sodium-glucose cotransporter 2 inhibitors.
    Kidney Int. 2024;106:12-15.
    >> Share

  13. FENG Y, Sun Z, Fu J, Zhong F, et al
    Podocyte-derived soluble RARRES1 drives kidney disease progression through direct podocyte and proximal tubular injury.
    Kidney Int. 2024;106:50-66.
    >> Share

    June 2024
  14. NANGAKU M
    SGLT2 inhibitor: 2-way superstar in nephrology?
    Kidney Int. 2024;105:1176-1177.
    >> Share

  15. KUME S, Packer M
    SGLT2 inhibitors act as metabolic transducers to restore healthy nutrient deprivation and surplus signaling in the kidney.
    Kidney Int. 2024;105:1172-1176.
    >> Share

  16. YAU K, Cherney DZI, van Raalte DH, Wever BE, et al
    Kidney protective mechanisms of SGLT2 inhibitors: evidence for a hemodynamic effect.
    Kidney Int. 2024;105:1168-1172.
    >> Share

  17. MCEVOY CM, Yuen DA
    Not too much, not too little-just the right amount: the story of YAP in the podocyte.
    Kidney Int. 2024;105:1157-1159.
    >> Share

    May 2024
  18. WADA Y, Kidokoro K, Kondo M, Tokuyama A, et al
    Evaluation of glomerular hemodynamic changes by sodium-glucose-transporter 2 inhibition in type 2 diabetic rats using in vivo imaging.
    Kidney Int. 2024 May 25:S0085-2538(24)00340-5. doi: 10.1016/j.kint.2024.
    >> Share

  19. HONG YA, Nangaku M
    Endogenous adenine as a key player in diabetic kidney disease progression: an integrated multiomics approach.
    Kidney Int. 2024;105:918-920.
    >> Share

  20. WANG L, Tian H, Wang H, Mao X, et al
    Disrupting circadian control of autophagy induces podocyte injury and proteinuria.
    Kidney Int. 2024;105:1020-1034.
    >> Share

    April 2024
  21. MURPHY DP, Wolfson J, Reule S, Johansen KL, et al
    A cohort study of sodium-glucose cotransporter-2 inhibitors after acute kidney injury among Veterans with diabetic kidney disease.
    Kidney Int. 2024 Apr 27:S0085-2538(24)00309-0. doi: 10.1016/j.kint.2024.
    >> Share

    March 2024
  22. NEGRI AL
    Sodium-glucose cotransporter 2 inhibitors in the treatment of refractory hypomagnesemia.
    Kidney Int. 2024;105:638.
    >> Share

  23. SHAH CV
    Sodium-glucose cotransporter 2 inhibition, epidermal growth factor, and magnesium homeostasis: is there a link?
    Kidney Int. 2024;105:638-639.
    >> Share

  24. CHEN JJ, Lee TH, Yang HY
    Exploring nontraditional cardiorenal advantages of SGLT-2 inhibitors and GLP-1 receptor agonists.
    Kidney Int. 2024;105:442-444.
    >> Share

    February 2024
  25. CHEN J, Wang X, He Q, Yang HC, et al
    Inhibition of transcriptional coactivator YAP Impairs the expression and function of transcription factor WT1 in diabetic podocyte injury.
    Kidney Int. 2024 Feb 27:S0085-2538(24)00160-1. doi: 10.1016/j.kint.2024.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016